Human cytomegalovirus DNA kinetics using a novel HCMV DNA quantitative assay in white blood cells of immunocompromised patients under Ganciclovir therapy.

@article{Payan1997HumanCD,
  title={Human cytomegalovirus DNA kinetics using a novel HCMV DNA quantitative assay in white blood cells of immunocompromised patients under Ganciclovir therapy.},
  author={Christopher Payan and Nary Veal and L Sarol and M Villarm{\'e} and Chan Ngohou and Paolo Riberi and S François and Norbert Ifrah and J. Loison and Jean Marie Chennebault and E Ric Pichard and S. Kouyoumdjian and Françoise Lunel},
  journal={Journal of virological methods},
  year={1997},
  volume={65 1},
  pages={
          131-8
        }
}
5 Citations
Multiplex polymerase chain reaction for the evaluation of cytomegalovirus DNA load in organ transplant recipients
TLDR
Evaluating the usefulness of a multiplex polymerase chain reaction (PCR) for the coamplification of HCMV‐DNA and β‐globin genomic sequence in polymorphonuclear leukocytes (PMNL) indicates that the system described is an efficient and reproducible diagnostic method easy to apply for routine diagnosis and therapeutic monitoring of transplanted patients.
Quantitation of Cytomegalovirus: Methodologic Aspects and Clinical Applications
SUMMARY Cytomegalovirus (CMV) is an important pathogen in transplant recipients and human immunodeficiency virus (HIV)-infected individuals. Major progress has been made in developing quantitative
Cytomegalovirus antigenemia surveillance in the treatment of cytomegalovirus disease in AIDS patients.
TLDR
Surveillance of quantitative cytomegalovirus (CMV) antigenemia among AIDS patients with CMV treated complications revealed a significantly longer survival for patients with retinitis when compared to those with extraocular complications, and for Patients with negative antigenemia after induction in comparison with those who failed to achieve it.

References

SHOWING 1-10 OF 17 REFERENCES
Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia, and DNAemia.
TLDR
Follow-up of HCMV infections in heart transplant recipients showed that PCR can detect viral appearance in blood 7-10 days earlier than assays for antigenemia/viremia, and viral disappearance from blood, as assessed by PCR, occurred weeks or months later than revealed by other assays.
Novel DNA assay for cytomegalovirus detection: comparison with conventional culture and pp65 antigenemia assay
TLDR
The pp65 antigenemia assay is a rapid and reliable method of detecting CMV and is preferable to culture, but the Murex HCS appears to be more sensitive for CMV detection.
Human cytomegalovirus viraemia in HIV-1-seropositive patients at various clinical stages of infection.
TLDR
Evidence of HCMV infection in circulating PMNL was found in 15 out of 29 ARC/AIDS patients examined, whereas no infection was detected among the 50 asymptomatic HIV-1-seropositive subjects.
Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation
TLDR
Whether the antigenemia assay is more sensitive than rapid culture methods to focus antiviral prophylaxis in marrow transplant patients must be determined in controlled studies.
Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival
TLDR
It is concluded that CMV load in the blood of AIDS patients is an important factor in the pathogenesis of retinitis, and quantification of CMV could be used to both select patients for controlled clinical trials and to optimize individual anti‐CMV induction therapy.
Lack of Clinical Utility of Cytomegalovirus Blood and Urine Cultures in Patients with HIV Infection
TLDR
To determine if CMV cultures are diagnostically or prognostically useful, a list of HIV- infected patients with their initial CMV blood and urine culture results was compiled from the records of the CMV reference laboratory used by the intramural AIDS program at the National Institutes of Health from 1982 to 1989.
Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation.
TLDR
Early treatment with ganciclovir in patients with positive surveillance cultures reduces the incidence of CMV disease and improves survival after allogeneic bone marrow transplantation.
Rapid screening for resistance to ganciclovir and foscarnet of primary isolates of human cytomegalovirus from culture-positive blood samples
A rapid screening assay for the detection of resistance to ganciclovir and foscarnet of primary isolates of human cytomegalovirus from culture-positive blood samples was developed by using single
Rapid determination of human cytomegalovirus susceptibility to ganciclovir directly from clinical specimen primocultures
TLDR
The rapid test, unlike conventional assays, is able to provide a result within 5 days after receipt of the specimen and could thus play a direct role in the therapeutic decision.
Impact of cytomegalovirus infection on organ transplant recipients.
  • R. Rubin
  • Medicine, Biology
    Reviews of infectious diseases
  • 1990
TLDR
Progress has been made in controlling CMV infection; hyperimmune anti-CMV globulin and certain antiviral drugs appear promising for prophylaxis, and the combination of hyperimmunoglobulin and ganciclovir appears promising for therapy.
...
1
2
...